Keywords: Janssen, Johnson & Johnson, Zytiga, Prostate cancer, BioMarin, Firdapse, LEMS, Scotland, SMC

Scottish regulator backs restricted NHS use of Janssen's Zytiga; negative on BioMarin's Firdapse

Article | 13 August 2012

Print This

The Scottish Medicines Consortium (SMC) announced yesterday that it has accepted Johnson & Johnson (NYSE: JNJ) subsidiary Janssen’s ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in